2026 Preview
Biopharma is back, but not everyone is benefitting. Qualified optimism is the mood music as the sector heads into 2026. Read on for insights into drugs, companies, R&D projects, and new launches that will dominate the news flow in 2026, and beyond.
Foreword
Innovation and Regulation
Analysis
Money, Markets and M&A
How We Help
Contact us for more information